ИСТИНА

Although antiretroviral therapy has made significant progress, the HIV epidemic still poses a serious threat to public health worldwide. One of the important steps towards the improvement of AIDS therapy and patients’ compliance is the development of long-acting injectable formulations (LAI) of antiretroviral drugs. Thus, recent clinical studies demonstrated high efficacy of the nanocrystal LAI of rilpivirine and cabotegravir. The objective of this study was to investigate an alternative approach to the rilpivirine LAI using the polylactic-co-glycolic acid microspheres (RPV-PLGA) as drug carriers.